Latanoprost Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
Condition:   Open Angle Glaucoma or Ocular Hypertension Interventions:   Drug: OPC-1085EL;   Drug: 0.005% Latanoprost Sponsor:   Otsuka Beijing Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2022 Category: Research Source Type: clinical trials